Clinical Trials Logo

X-Linked Retinitis Pigmentosa clinical trials

View clinical trials related to X-Linked Retinitis Pigmentosa.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06275620 Enrolling by invitation - Clinical trials for X-Linked Retinitis Pigmentosa

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

Start date: November 14, 2023
Phase: Phase 2
Study type: Interventional

This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a full-length AAV vector-based gene therapy targeting RPGR protein.

NCT ID: NCT03584165 Enrolling by invitation - Choroideremia Clinical Trials

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

SOLSTICE
Start date: June 4, 2018
Phase: Phase 3
Study type: Interventional

The objective of the study is to evaluate the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111 and who have exited an antecedent study; these treated participants will be compared with untreated control participants who have exited the STAR (NCT03496012) study and BIIB112 in participants with X-linked retinitis pigmentosa (XLRP) who have been previously treated with BIIB112 and who have exited an antecedent study.